ImmunityBio (IBRX) Capital Expenditures (2014 - 2026)

For the trailing twelve months through Jun 30, 2026, Capital Expenditures at ImmunityBio was $6.94 million, down 2.4% year-over-year; for FY2025, it came in at $3.85 million, down 44.2% from FY2024.

• Annual Capital Expenditures has declined for three consecutive years, though with a five-year compound annual growth rate of 18.2% (FY2020 to FY2025).
• In prior years, ImmunityBio's Capital Expenditures was $6.89 million in FY2024 (-77.5%), $30.58 million in FY2023 (-60.9%), $78.16 million in FY2022 (+132.9%) and $33.56 million in FY2021.
• The Q2 2026 figure stands as the highest quarterly Capital Expenditures since Q4 2023.
• On a year-over-year basis, Capital Expenditures increased in three of the last eight quarters, with growth averaging 8.4%.
• The strongest year-over-year quarter for Capital Expenditures in the past five years was Q3 2021, with growth of 293.0%; the weakest was Q2 2024, with a decline of 91.5%.
• According to Business Quant data, Capital Expenditures for the three prior quarters was $1.78 million (Q1 2026), $903,000 (Q4 2025) and $741,000 (Q3 2025).